Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 17 Neoplasm Metastasis 3 Endometrial Neoplasms 2 Anatomic Stage II Breast Cancer AJCC v8 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Locally Advanced (Inoperable) or Metastatic Breast Cancer 1 Liposarcoma 1 Leiomyosarcoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 HR+/HER2- Breast Cancer 1 HER2 Negative Breast Cancer 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 ER+ HER2- Advanced Breast Cancer 1 Breast Neoplasms, Male 1 Breast Diseases 1 Advanced Breast Cancer 1

Interventions

Letrozole 4 Fulvestrant 2 Anastrozole 2 toripalimab 1 ribociclib 1 palbociclib 1 exemestane 1 elacestrant 1 disitamab vedotin 1 abemaciclib 1 Paclitaxel 1 Lead 1 Injections 1 Goserelin 1 AZD9833 1 AZD5305 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × ribociclib × 30 days × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡